List of titles of eurotau abstracts

List of speakers

More to come…

Frank Bennett, Ionis, USA

Don Cleveland, UC San Diego, USA

Ilse Dewachter, Hasselt, Belgium

ApoE, inflammation and tau in AD: a road towards multi-targeted therapies

Stephanie Fowler, London, UK

Short tau filaments are packaged into extracellular vesicles in AD brain

Michel Goedert, Cambridge, UK

Cryo-EM structures of amyloid filaments from human brains

Maud Gratuze, Marseille, France

TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4

Jürgen Götz, Brisbane, Australia

Tau in Alzheimer’s disease – from pathomechanistic studies to therapeutic ultrasound as a treatment modality

Bernard Hanseeuw, Louvain, Belgium

Specific post-translational modifications of the soluble tau protein distinguish between Alzheimer’s disease, 4R-, and 3R-tauopathies

Eckhard Mandelkow, Germany

Pierre Maquet, Liège, Belgium

Early brainstem tau relates to cortical excitability in healthy aging

Ana Melo de Farias, Brazil & France

Alzheimer’s risk gene PTK2B effects TAU phosphorylation in human induced neurons

Tim Miller, MO, USA

Leonard Petrucelli, FL, USA

TMEM106b in FTLD-TDP and PSP

Naruhiko Sahara, Inage, Chiba, Japan

Dissecting mechanisms of tauopathy using in vivo multimodal imaging techniques on tauopathy mouse models

Wiep Scheper, Amsterdam, NL

Understanding Granulovacuolar Degeneration Bodies: A neuron-specific response to tau pathology

Maria Grazia Spillantini, Cambridge, UK

Glial cells in P301S tau transgenic mice show ageing-related features

Patrik Verstreken, Leuven, Belgium

Tau toxicity at the synapse

Susanne Wegmann, Berlin, Germany

Tau aggregation and liquid droplets

Claude Wischik, TauRx

Phase 3 outcomes for tau aggregation inhibitor in Alzheimer’s

Title of Eurotau abstracts

  • A 3D human co-culture to model neuron-astrocyte interactions in tauopathies
  • A brain-seeded fibril amplification models the aggregation process of tau in Alzheimer’s disease for drug discovery
  • A direct CSF-to-blood Tau transport: the tanycytic clearance.
  • A natural variant of the autophagic receptor NDP52 as a new target for Alzheimer’s Disease
  • A new mechanism of endogenous Tau aggregation through ApoE/neuroproteasome complexes
  • Alzheimer’s risk gene PTK2B affects TAU phosphorylation  in human induced neurons
  • Analysis of neurofilament light alterations in brain versus blood in TauP301S and 5xFAD mice.
  • Analysis of the molecular factors driving neuronal pathology in Alzheimer’s Disease using GeneFunnel, a novel gene set enrichment and network analysis tool
  • Anti-S100B nanobodies as modulators of Tau aggregation
  • APOE deficiency rescues tau pathology and tau driven neurodegeneration in P301S mouse model
  • ApoE, inflammation and tau in AD: a road towards multi-targeted therapies.
  • Chaperone modulation of tau aggregation and condensation
  • Chaperone regulation of tau liquid-liquid phase separation
  • Characterizing the interaction between Tau and tubulin using SDL-EPR spectroscopy
  • CK1δ activity is required for the accumulation of tau-induced granulovacuolar degeneration bodies
  • Consequences of a high-fat diet during lactation in a mouse model of tauopathy
  • Contribution of phosphorylation and aggregation to Tau-mediated toxicity.
  • Cryo-EM Structures of Amyloid Filaments from Human Brains
  • Developing the Drosophila wing disc as a model system of Tau internalization and trafficking
  • Development of an AAV-based model of tauopathy targeting the dentate gyrus to study the role of microglia in the spreading of toxic tau species
  • Differential implication of large and small extracellular vesicles in tau seeding
  • Dissecting mechanisms of tauopathy using in vivo multimodal imaging techniques on tauopathy mouse models
  • Dual Optical Techniques to Study Liquid-Liquid Phase Separation of Tau
  • Early brainstem tau relates to cortical excitability in healthy aging
  • Effects of adenosine A2A receptor astrocytic upregulation in the mouse hippocampus
  • Effects of spermidine on tau-induced mitochondrial dysfunction
  • Elucidating key components in Alzheimer’s disease progression.
  • Enriched environment- non-pharmacological alternative to slow down propagation of AD tau pathology and improve cognitive functions
  • Evaluation of astrocytes morphological changes in tauopathies
  • Extracellular tau impairs the interaction of tau with microtubules in model neurons: A new cellular model for understanding tauopathies
  • Free cholesterol regulates neuronal pTau
  • From early endosomal deficits to severe dendrite collapse: tau pathology in human and mouse neurons
  • Frontotemporal dementia-associated tau mutations induce altered nucleolar structure before cell death
  • Glutamatergic drivers of Tau pathology in the human thalamus 
  • High amount and fast production of tauc3 in ps19 mice
  • How does insulin resistance increase risk of Alzheimer’s disease?
  • Human MAPT knock-in mice that harbor familial tauopathy-causing mutations
  • Human Tau aggregates are permissive to Protein Synthesis Dependent Memory in Drosophila Tauopathy models
  • Human tau-isoform specific effects in Drosophila CNS
  • Hydromethylthionine first, rivastigmine second: cognitive effects of single versus combination therapies in tau transgenic mice
  • Hydromethylthionine induces long-term and sustained decreases in truncated tau in a mouse model of frontotemporal dementia
  • Identify critical regulators of pre-synaptic tau release
  • Impact of tau and amyloid-beta lesions on the transcriptome expression in a primate model of Alzheimer’s Disease.
  • Impact of tau on the ER-mitochondria coupling
  • Impact of Tau protein on the nuclear envelope and chromatin structure
  • In vitro aggregation of tau by protein misfolding cyclic amplification
  • In vitro and in vivo artefacts when analysing tau phosphorylation by Western blot or immunohistochemistry.
  • In vivo modulation of Tau pathology and neurodegeneration by NLRP3 inflammasome
  • Interaction between Tau and nuclear transport proteins in Tau protein-associated dementias
  • Interaction of Alzheimer’s disease genetic risk factors: Characterization of PYK2 AND BIN1 protein-protein interaction
  • Interaction of tau and Aβ in mouse models of Alzheimer’s disease
  • Intraneuronal tau aggregation induces the integrated stress response in astrocytes
  • Investigating BIN1 involvement in tau handling and extracellular vesicle secretion in iPSC-microglia
  • Investigating role of plumbagin in preventing neurodegenerative diseases via inhibiting the tau phosphorylating kinase MARK4
  • Investigating the contribution of an intronic variation at the TRIM11/TRIM17 locus to pathological and clinical heterogeneity in Progressive Supranuclear Palsy
  • Investigating the endocytic mechanism of pathological tau at the synapse
  • Investigating the pathological role of Tau associated with Alzheimer’s disease on the nucleolus of neuronal (SH-SY5Y) cells
  • Investigating the potential of the insulin-sensitizing drug Metformin in ameliorating Tau pathology in cellular and Drosophila models
  • Investigating the role of ERK, JNK and p38 in the phosphorylation of Thr175 tau associated with traumatic brain injury.
  • Investigating the synaptic mechanisms of the spread of wild type and P301S 1N4R human tau in in vitro and in vivo models
  • Isoform-specific siRNAs: A potential therapeutic approach for 4R tauopathies.
  • Isolation of spontaneously-released brain extracellular vesicles: implications for brain pathology
  • Lewy body co-pathology contributes to frontal lobe atrophy in Alzheimer’s disease and primary age-related tauopathy (PART)
  • Live-cell visualization of tau aggregation in human neurons
  • Local tau reduction rescues pathological phenotypes in a preclinical model of tauopathy
  • MAPT mutations in Amyotrophic Lateral Sclerosis
  • MAPT S305 mutations alter neuron and astrocyte function
  • Mass-spectrometry analysis of a tau hyperphosphorylation model reveals increased stathmin-2 expression as an inducer of microtubule destabilization
  • Methods to assess the activity of drug candidates on tau aggregation and tau microtubule dynamics
  • Mical modulates Tau toxicity via cysteine oxidation in vivo
  • Mutations in tau protein influence aggregation propensity through conformation modulation
  • NanoBit tau biosensors bring new insights into the molecular events triggering early pathological tau transformation and seeding activity
  • NanoTarget : An original approach for intracellular delivery of anti-tau single domain antibodies
  • Neuronal identity defines a-synuclein and tau toxicity
  • Neuronal vulnerability to tau-mediated toxicity is characterized by a broad spectrum of varying responses
  • Neuroprotective effects of CB2 cannabinoid receptor antagonists’ treatment in TAU-dependent Frontotemporal Dementia
  • New Thiazole-Flavone Hybrid Compounds Binding to Tau Protein and With Antitumor Activity Against Glioblastoma
  • Oligomerization of Tau on Microtubules
  • Optimization and selection of VHHs targeting Tau nucleation core
  • Pathogenic Tau reactivates a developmental pruning pathway
  • Peptide-based inhibitors of Tau aggregation as a potential therapeutic for Alzheimer’s disease and other Tauopathies
  • Persistent pain causes Tau-mediated hippocampal malfunction and memory deficits
  • Phase 3 outcomes for tau aggregation inhibitor in Alzheimer’s
  • Phase separation of a paired-helical filament forming region of tau
  • Phosphorylated tau is present in the human nucleus incertus of the brain
  • Physicochemical characterization of cellular Tau accumulations and aggregates using advanced imaging modalities
  • Presynaptic toxicity of the ad risk gene bin1
  • Protection against tauopathy is influenced by sex
  • Proteomic signature of vulnerable neurons in Alzheimer’s disease brains
  • Purinergic P2Y12 receptor-mediated endocytic accumulation of Tau oligomers with β-arrestin-1 and follow lysosomal degradation in microglia
  • Pyk2 and Tau interaction promotes synaptic localization of phospho-Tau 181/Tau in neurons
  • Regulation of Tau protein phosphorylation by kinase O-GlcNAcylation and its implication in fibrillar aggregation
  • Revisiting the involvement of tau in complex neural network remodelling: analysis of the extracellular neuronal activity in organotypic brain slice co-cultures
  • Screening tyrosine kinases for their involvement in synaptotoxicity induced by tau microtubule-binding region fibrils
  • Short tau filaments are packaged into extracellular vesicles in AD brain
  • Silencing of phagocytic receptor MERTK in astrocytes alleviates Tau pathology in rodent models of primary Tauopathies
  • Specific tau PTMs distinguish AD, 4R &3R tauopathy
  • Study of the brain-gut axis in a mouse model of Alzheimer’s disease
  • Study of the interactions between the Alzheimer’s disease genetic risk factors BIN1 and PTK2B
  • Synaptogyrin-3: A potential target against Tau-induced pre-synaptic defects?
  • Targeting intracellular tau with intrabodies
  • Targeting of pathological tau protein in interstitial fluid using anti-PHF6 minibody
  • Tau aggregation and liquid droplets
  • Tau biology, tau vaccines and therapeutic ultrasound
  • Tau secretion is driven by circadian variations of body temperature during the sleep/wake cycle: implications for tau spreading in Alzheimer’s disease
  • Tau toxicity at the synapse
  • Tauopathy-associated PERK variants impair signal transduction and promote tau aggregation
  • Temperature and Concentration Dependent Alteration in Tau Liquid–liquid Phase Separation through Hyperphosphorylation
  • The effect of the ApoE Christchurch mutation on AD pathology in a combined amyloid and tau mouse model
  • The role of human microglia and microglial LRRK2 in tau pathogenesis
  • The role of tau isoforms in neuronal vulnerability
  • TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4
  • Ubiquitination as a modulator of tau aggregation and condensation
  • Understanding Granulovacuolar Degeneration Bodies: A neuron-specific response to tau pathology
  • Understanding Granulovacuolar Degeneration Bodies: A neuron-specific response to tau pathology
  • Validation of an AD brain seed-injection model in hTau mice
  • Validation of therapeutic siRNAs in hiPSCs-derived neurons, a model of FTDP-17
  • Visualization of tau pathology using in situ cryo-ET
  • Zika virus infection of immunocompetent mice leads to a persistent disease associated microglia (DAM)-like phenotype and the pathological phosphorylation of Tau protein.